Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
Hepatocellular carcinoma often develops in the context of chronic liver disease. It is the sixth most frequently diagnosed cancer and the third most common cause of cancer-related mortality worldwide. Although the mainstay of therapy is surgical resection, most patients are not eligible because of l...
Main Authors: | Daniel M. Girardi, Lara P. Sousa, Thiago A. Miranda, Fernanda N. C. Haum, Gabriel C. B. Pereira, Allan A. L. Pereira |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/6/1680 |
Similar Items
-
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
by: Gok Yavuz B, et al.
Published: (2021-09-01) -
Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives
by: Daniel M. Girardi, et al.
Published: (2020-12-01) -
Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response
by: Penghui He, et al.
Published: (2022-11-01) -
Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing
by: Fan Yang, et al.
Published: (2022-03-01) -
CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target
by: Qianwei Jiang, et al.
Published: (2023-07-01)